New Zealand markets close in 6 hours 28 minutes
  • NZX 50

    12,165.00
    +12.84 (+0.11%)
     
  • NZD/USD

    0.6478
    -0.0024 (-0.38%)
     
  • ALL ORDS

    7,728.50
    +18.80 (+0.24%)
     
  • OIL

    75.78
    -0.63 (-0.82%)
     
  • GOLD

    1,926.30
    -16.50 (-0.85%)
     

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

Nemaura Medical, Inc
Nemaura Medical, Inc

Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

Presentation Date: December 7, 2022
Time: 9:00am EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2937/47190

Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. To attend the conference and request a meeting, register here:

https://planetmicrocapshowcase.com/signup

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham (Media)
CORE IR
917-885-7378
julesa@coreir.com

Bret Shapiro (Investors)
Senior Managing Partner
CORE IR
(561) 479.8566
brets@coreir.com